NCT06416410 2025-04-04
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
Clinical Trials
4 trialsNCT03190239 2024-02-28
XQonc-007
Xinqiao Hospital of Chongqing
Phase 2 Withdrawn
NCT06028633 2023-09-13
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
Peking University First Hospital
Phase 2 Not yet recruiting
NCT04416035 2020-08-31
NSCLC
Zhejiang Teruisi Pharmaceutical Inc.
Phase 3 Unknown